Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis

I. Caruso, N. Principi, G. D'Urbino, S. Santandrea, L. Boccassini, F. Montrone, P. C. Sarziputtini, A. Bombaci, A. Bozzato, V. Azzolini, D. Dell' Acqua

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The therapeutic activity of rifamycin SV administered by the intra-articular route was evaluated in 52 children with juvenile rheumatoid arthritis (oligopolyarthritis). Each active joint was injected once a week for 10 weeks; thereafter patients were followed for 3 - 48 months. The number of active joints and joints with limitation of motion, the erythrocyte sedimentation rate (ESR) and C-reactive protein improved significantly at the end of the treatment cycle, with progressive improvement during the subsequent period of observation. At 48-month of follow-up, 78% of joints did not present signs of inflammation; and 66% of joints showed no functional limitations. Joints without radiological lesions at baseline and large joints responded best to the rifamycin treatment. Persistent knee effusions were reabsorbed completely in most cases during the treatment and within the first 6 months of follow-up. Recurrences of synovitis were observed in 7% of joints. De novo radiological lesions in initially undamaged joints occurred during the second year of follow-up in only 10% of patients. At 24 months, 62% of patients with oligoarthritis and 24% with polyarthritis showed complete remission in all affected joints and recovered movement in all those joints which had shown limitations at baseline. There was also a normalization of inflammatory indexes (ESR, C-reactive protein) and regression of general features of disease. Further long term studies are now required to confirm these promising preliminary results.

Original languageEnglish
Pages (from-to)243-256
Number of pages14
JournalJournal of International Medical Research
Volume21
Issue number5
Publication statusPublished - 1993

Fingerprint

Juvenile Arthritis
Sedimentation
Infiltration
C-Reactive Protein
Joints
Blood Sedimentation
rifamycin SV
Synovitis
Therapeutics
Arthritis
Knee
Observation

Keywords

  • Intra-articular
  • Juvenile rheumatoid arthritis
  • Oligoarthritis
  • Polyarthritis
  • Rifamycin SV

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis. / Caruso, I.; Principi, N.; D'Urbino, G.; Santandrea, S.; Boccassini, L.; Montrone, F.; Sarziputtini, P. C.; Bombaci, A.; Bozzato, A.; Azzolini, V.; Dell' Acqua, D.

In: Journal of International Medical Research, Vol. 21, No. 5, 1993, p. 243-256.

Research output: Contribution to journalArticle

Caruso, I, Principi, N, D'Urbino, G, Santandrea, S, Boccassini, L, Montrone, F, Sarziputtini, PC, Bombaci, A, Bozzato, A, Azzolini, V & Dell' Acqua, D 1993, 'Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis', Journal of International Medical Research, vol. 21, no. 5, pp. 243-256.
Caruso, I. ; Principi, N. ; D'Urbino, G. ; Santandrea, S. ; Boccassini, L. ; Montrone, F. ; Sarziputtini, P. C. ; Bombaci, A. ; Bozzato, A. ; Azzolini, V. ; Dell' Acqua, D. / Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis. In: Journal of International Medical Research. 1993 ; Vol. 21, No. 5. pp. 243-256.
@article{52119d31aab5478590e752fcfad8abdc,
title = "Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis",
abstract = "The therapeutic activity of rifamycin SV administered by the intra-articular route was evaluated in 52 children with juvenile rheumatoid arthritis (oligopolyarthritis). Each active joint was injected once a week for 10 weeks; thereafter patients were followed for 3 - 48 months. The number of active joints and joints with limitation of motion, the erythrocyte sedimentation rate (ESR) and C-reactive protein improved significantly at the end of the treatment cycle, with progressive improvement during the subsequent period of observation. At 48-month of follow-up, 78{\%} of joints did not present signs of inflammation; and 66{\%} of joints showed no functional limitations. Joints without radiological lesions at baseline and large joints responded best to the rifamycin treatment. Persistent knee effusions were reabsorbed completely in most cases during the treatment and within the first 6 months of follow-up. Recurrences of synovitis were observed in 7{\%} of joints. De novo radiological lesions in initially undamaged joints occurred during the second year of follow-up in only 10{\%} of patients. At 24 months, 62{\%} of patients with oligoarthritis and 24{\%} with polyarthritis showed complete remission in all affected joints and recovered movement in all those joints which had shown limitations at baseline. There was also a normalization of inflammatory indexes (ESR, C-reactive protein) and regression of general features of disease. Further long term studies are now required to confirm these promising preliminary results.",
keywords = "Intra-articular, Juvenile rheumatoid arthritis, Oligoarthritis, Polyarthritis, Rifamycin SV",
author = "I. Caruso and N. Principi and G. D'Urbino and S. Santandrea and L. Boccassini and F. Montrone and Sarziputtini, {P. C.} and A. Bombaci and A. Bozzato and V. Azzolini and {Dell' Acqua}, D.",
year = "1993",
language = "English",
volume = "21",
pages = "243--256",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "5",

}

TY - JOUR

T1 - Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis

AU - Caruso, I.

AU - Principi, N.

AU - D'Urbino, G.

AU - Santandrea, S.

AU - Boccassini, L.

AU - Montrone, F.

AU - Sarziputtini, P. C.

AU - Bombaci, A.

AU - Bozzato, A.

AU - Azzolini, V.

AU - Dell' Acqua, D.

PY - 1993

Y1 - 1993

N2 - The therapeutic activity of rifamycin SV administered by the intra-articular route was evaluated in 52 children with juvenile rheumatoid arthritis (oligopolyarthritis). Each active joint was injected once a week for 10 weeks; thereafter patients were followed for 3 - 48 months. The number of active joints and joints with limitation of motion, the erythrocyte sedimentation rate (ESR) and C-reactive protein improved significantly at the end of the treatment cycle, with progressive improvement during the subsequent period of observation. At 48-month of follow-up, 78% of joints did not present signs of inflammation; and 66% of joints showed no functional limitations. Joints without radiological lesions at baseline and large joints responded best to the rifamycin treatment. Persistent knee effusions were reabsorbed completely in most cases during the treatment and within the first 6 months of follow-up. Recurrences of synovitis were observed in 7% of joints. De novo radiological lesions in initially undamaged joints occurred during the second year of follow-up in only 10% of patients. At 24 months, 62% of patients with oligoarthritis and 24% with polyarthritis showed complete remission in all affected joints and recovered movement in all those joints which had shown limitations at baseline. There was also a normalization of inflammatory indexes (ESR, C-reactive protein) and regression of general features of disease. Further long term studies are now required to confirm these promising preliminary results.

AB - The therapeutic activity of rifamycin SV administered by the intra-articular route was evaluated in 52 children with juvenile rheumatoid arthritis (oligopolyarthritis). Each active joint was injected once a week for 10 weeks; thereafter patients were followed for 3 - 48 months. The number of active joints and joints with limitation of motion, the erythrocyte sedimentation rate (ESR) and C-reactive protein improved significantly at the end of the treatment cycle, with progressive improvement during the subsequent period of observation. At 48-month of follow-up, 78% of joints did not present signs of inflammation; and 66% of joints showed no functional limitations. Joints without radiological lesions at baseline and large joints responded best to the rifamycin treatment. Persistent knee effusions were reabsorbed completely in most cases during the treatment and within the first 6 months of follow-up. Recurrences of synovitis were observed in 7% of joints. De novo radiological lesions in initially undamaged joints occurred during the second year of follow-up in only 10% of patients. At 24 months, 62% of patients with oligoarthritis and 24% with polyarthritis showed complete remission in all affected joints and recovered movement in all those joints which had shown limitations at baseline. There was also a normalization of inflammatory indexes (ESR, C-reactive protein) and regression of general features of disease. Further long term studies are now required to confirm these promising preliminary results.

KW - Intra-articular

KW - Juvenile rheumatoid arthritis

KW - Oligoarthritis

KW - Polyarthritis

KW - Rifamycin SV

UR - http://www.scopus.com/inward/record.url?scp=0027723499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027723499&partnerID=8YFLogxK

M3 - Article

C2 - 8112482

AN - SCOPUS:0027723499

VL - 21

SP - 243

EP - 256

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 5

ER -